What question did this study set out to answer?

This study aims to explore how Xiaobanxia Decoction (XBXD) can alleviate intestinal damage caused by cisplatin through the modulation of UFL1-mediated endoplasmic reticulum stress.

June 3, 2026Open Access

Xiaobanxia Decoction attenuates cisplatin-induced intestinal damage via restoring UFL1-mediated endoplasmic reticulum stress in a rat pica model

Key Points

This study aims to explore how Xiaobanxia Decoction (XBXD) can alleviate intestinal damage caused by cisplatin through the modulation of UFL1-mediated endoplasmic reticulum stress.
64 male Sprague-Dawley rats were randomly assigned to 4 groups: control, cisplatin model, ondansetron, and XBXD.
Cisplatin was administered via intraperitoneal injection to create an intestinal injury model.
Histopathological examinations and serum biomarker assessments were performed in all groups.
XBXD significantly improved pica behavior and reduced gastrointestinal inflammation in cisplatin-treated rats.
Serum levels of reactive oxygen species, interleukin-6, and tumor necrosis factor-alpha were notably decreased (P < 0.01).
XBXD restored UFL1 expression and mitigated cisplatin-induced endoplasmic reticulum stress (P < 0.01 at 24 hours).

Abstract

Objective: Xiaobanxia Decoction (XBXD) is a traditional antiemetic formula effective in preventing chemotherapy-induced nausea and vomiting (CINV), but its mechanism remains unclear. This study aimed to investigate whether it attenuates cisplatin-induced intestinal damage by restoring UFM1-specific ligase 1 (UFL1)-mediated endoplasmic reticulum stress (ERS) in a rat model of pica. Methods: Sixty-four 7-week-old male Sprague-Dawley rats were randomly assigned to four groups: control group, cisplatin model group, ondansetron-treated group, and XBXD-treated group ( n = 16 per group). A rat intestinal injury model was established by intraperitoneal injection of cisplatin. Kaolin intake was recorded every 24 hours. Histopathological examination was performed on the gastric antrum and ileum. Serum levels of reactive oxygen species, interleukin-6, tumor necrosis factor-α, diamine oxidase, lipopolysaccharide, and Mucin2 in the ileum were measured using enzyme-linked immunosorbent assay. Immunohistochemistry and immunoblotting were used to measure protein levels of Claudin-1, Occludin, UFL1, IRE1, p-IRE1, XBP1, Bip, and CHOP in the ileum. Results: XBXD improved pica behavior in cisplatin-treated rats and ameliorated gastrointestinal inflammatory injury. XBXD reduced the elevated serum levels of reactive oxygen species, interleukin-6, tumor necrosis factor-α, diamine oxidase, and lipopolysaccharide (all P < 0.01) induced by cisplatin. XBXD also reversed the significant decrease in Mucin2 expression ( P < 0.05, P < 0.01, respectively) in the rat ileum caused by cisplatin. The decreased expression of Claudin-1 and Occludin ( P < 0.01 in Occludin 24 and 72 hours; P < 0.05 in Claudin-1 24 and 72 hours) induced by cisplatin was alleviated by XBXD treatment. In the ileum, XBXD restored UFL1 expression ( P < 0.01 in 24 hours; P < 0.05 in 72 hours) and regulated cisplatin-induced ERS. Conclusion: XBXD attenuates cisplatin-induced intestinal damage, possibly by restoring UFL1-mediated ERS.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Feng et al. (Mon,) studied this question.

synapsesocial.com/papers/6a1fc64adee9eb8c0dce7664 https://doi.org/https://doi.org/10.1097/st9.0000000000000127

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper